Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Solute exchange through gap junctions lessens the adverse effects of inactivating mutations in metabolite-handling genes.
PMID 36107487 · PMC9534548 · eLife · 2022 · 8 claims · 8 setups
Colorectal cancer (CRC) cells are coupled by gap junctions assembled predominantly from Cx26 (GJB2)
-
Full-text index only
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
PMID 41534092 · PMC13044530 · Cancer research · 2026 · 8 claims · 8 setups
SWI/SNF-targeting PROTAC treatment reduces viability of CRPC-WNT (AR-negative) cell lines and organoids, not just AR-dependent CRPC
-
Full-text index only
Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach.
PMID 18829526 · PMC2692251 · Cancer research · 2008 · 7 claims · 6 setups
Global association of HuR and AUF1 with target mRNAs changes substantially and largely reciprocally between MCT-1-transformed and nontransformed MCF10A cells
-
Has reproduction · 50
Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
PMID 33420019 · PMC7794422 · Nature communications · 2021 · 8 claims · 8 setups
SNAI2 is highly expressed in FN-RMS tumors and cell lines compared to normal tissue
-
Full-text index only
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
PMID 19946270 · PMC4002225 · Nature genetics · 2010 · 8 claims · 8 setups
PARK2 is a frequently and specifically targeted gene within recurrent 6q25.2-q27 copy number losses in glioblastoma and colon cancer
-
Has reproduction · 85
Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
PMID 33634984 · PMC7882098 · Clinical and translational medicine · 2021 · 8 claims · 8 setups
JMJD6 is identified as a potent epigenetic vulnerability/fitness gene in RCC by integrating GeCK CRISPR screening data with TCGA-KIRC epigenetic regulator survival analysis